Inflammatory bowel disease: Sorting out the treatment options

被引：23

作者：

Wolf, JM ^{[1
]}

Lashner, BA ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Dept Gastroenterol, Ctr Inflammatory Bowel Dis, Cleveland, OH 44195 USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2002年 / 69卷 / 08期

关键词：

D O I：

10.3949/ccjm.69.8.621

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An increasing array of treatments such as immunosuppressive drugs and tumor necrosis factor inhibitors can offer patients with ulcerative colitis and Crohn disease improved relief from symptoms with fewer adverse effects. Several additional drugs have shown promise, including nicotine, antimicrobials, and heparin.

引用

页码：621 / +

页数：9

共 58 条

[1] Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment [J].

Aithal, GP ;

Mansfield, JC .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (08) :1101-1108

[2] Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis [J].

Baert, FJ ;

D'Haens, GR ;

Peeters, M ;

Hiele, MI ;

Schaible, TF ;

Shealy, D ;

Geboes, K ;

Rutgeerts, PJ .

GASTROENTEROLOGY, 1999, 116 (01) :22-28

[3] Budesonide versus prednisone in the treatment of active Crohn's disease [J].

Bar-Meir, S ;

Chowers, Y ;

Lavy, A ;

Abramovitch, D ;

Sternberg, A ;

Leichtmann, G ;

Reshef, R ;

Odes, S ;

Moshkovitz, M ;

Bruck, R ;

Eliakim, R ;

Maoz, E ;

Mittmann, U .

GASTROENTEROLOGY, 1998, 115 (04) :835-840

[4] Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease [J].

Belluzzi, A ;

Brignola, C ;

Campieri, M ;

Pera, A ;

Boschi, S ;

Miglioli, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (24) :1557-1560

[5] The relationship between infliximab treatment and lymphoma in Crohn's disease [J].

Bickston, SJ ;

Lichtenstein, GR ;

Arseneau, KO ;

Cohen, RB ;

Cominelli, F .

GASTROENTEROLOGY, 1999, 117 (06) :1433-1437

[6] RISK OF ULCERATIVE-COLITIS AMONG FORMER AND CURRENT CIGARETTE SMOKERS [J].

BOYKO, EJ ;

KOEPSELL, TD ;

PERERA, DR ;

INUI, TS .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (12) :707-710

[7] A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL OF CYCLOSPORINE THERAPY IN ACTIVE CHRONIC CROHNS-DISEASE [J].

BRYNSKOV, J ;

FREUND, L ;

RASMUSSEN, SN ;

LAURITSEN, K ;

DEMUCKADELL, OS ;

WILLIAMS, N ;

MACDONALD, AS ;

TANTON, R ;

MOLINA, F ;

CAMPANINI, MC ;

BIANCHI, P ;

RANZI, T ;

DIPALO, FQ ;

MALCHOWMOLLER, A ;

THOMSEN, OO ;

TAGEJENSEN, U ;

BINDER, V ;

RIIS, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (13) :845-850

[8]

BRZEZINSKI A, 1995, CLEV CLIN J MED, V62, P317

[9] Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables [J].

Camma, C ;

Giunta, M ;

Rosselli, M ;

Cottone, M .

GASTROENTEROLOGY, 1997, 113 (05) :1465-1473

[10] Oral budesonide is as effective as oral prednisolone in active Crohn's disease [J].

Campieri, M ;

Ferguson, A ;

Doe, W ;

Persson, T ;

Nilsson, LG ;

Malchow, H ;

Prantera, C ;

Mani, V ;

OMorain, C ;

Selby, W ;

Pallone, F ;

diPietralata, MM ;

Sjodahl, R ;

Florin, T ;

Smith, P ;

Bianchi, P ;

Lofberg, R ;

Rutgeerts, P ;

Smallwood, R ;

Lamers, HW ;

TasmanJones, C ;

Hunter, JO ;

Hodgson, H ;

Danielsson, A ;

Lee, FI ;

Piacitelli, G ;

Giovanni, S ;

Ellis, A ;

Weir, DG .

GUT, 1997, 41 (02) :209-214

← 1 2 3 4 5 6 →